Abstract: The invention provides a p38 MAPK inhibitor of Formula I, or a pharmaceutically acceptable salt or solvate thereof: for use in the treatment or prevention of hypercytokinemia in a human patient; wherein R is C1-3alkyl, optionally substituted by one or more halo, NR1R2 or hydroxy, and R1and R2 are independently H, halo or C1-3alkyl, optionally substituted by one or more F. Also provided are compositions for use in the treatment or prevention of hypercytokinemia comprising the p38 MAPK inhibitor of Formula I; and methods for treating or preventing hypercytokinemia in a human patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a p38 MAPK inhibitor of Formula I. The invention also provides a p38 MAPK inhibitor and an antimicrobial agent, such as an antiviral agent, for use in the treatment or prevention of hypercytokinemia.
Type:
Application
Filed:
September 23, 2022
Publication date:
March 30, 2023
Applicant:
Orph Pharma IP Company Limited
Inventors:
Adrian Huw Davies, Pui-Man Choy, Vinay Saunders, Basma Bahsoun, Surender Vashist, Neil Edward Torbett, Paul Andrew Whittaker
Abstract: The invention provides a p38 MAPK inhibitor of Formula I, or a pharmaceutically acceptable salt or solvate thereof: Formula I for use in the treatment or prevention of hypercytokinemia in a human patient; wherein R is C1-3alkyl, optionally substituted by one or more halo, NR1R2 or hydroxy, and R1 and R2 are independently H, halo or C1-3alkyl, optionally substituted by one or more F. Also provided are compositions for use in the treatment or prevention of hypercytokinemia comprising the p38 MAPK inhibitor of Formula I; and methods for treating or preventing hypercytokinemia in a human patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a p38 MAPK inhibitor of Formula I. The invention also provides a p38 MAPK inhibitor and an antimicrobial agent, such as an antiviral agent, for use in the treatment or prevention of hypercytokinemia.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
February 28, 2023
Assignee:
Orph Pharma IP Company Limited
Inventors:
Adrian Huw Davies, Pui-Man Choy, Vinay Saunders, Basma Bahsoun, Surender Vashist, Neil Edward Torbett, Paul Andrew Whittaker
Abstract: A p38 MAPK inhibitor for use in the treatment or prevention of severe influenza in a human patient. In some embodiments, the severe influenza may be characterised by hypercytokinemia involving elevated levels of one or more pro-inflammatory cytokines. The p38 MAP kinase inhibitor may act to inhibit the release of such pro-inflammatory mediators from endothelial cells. In some embodiments, the p38 MAP kinase inhibitor may inhibit the release of IP 10 from endothelial cells, preferably in a dose-dependent manner.
Type:
Application
Filed:
May 6, 2022
Publication date:
September 1, 2022
Applicant:
Orph Pharma IP Company Limited
Inventors:
Paul Andrew Whittaker, Neil Edward Torbett
Abstract: A p38 MAPK inhibitor for use in the treatment or prevention of severe influenza in a human patient. In some embodiments, the severe influenza maybe characterised by hypercytokinemia involving elevated levels of one or more pro-inflammatory cytokines. The p38 MAP kinase inhibitor may act to inhibit the release of such pro-inflammatory mediators from endothelial cells. In some embodiments, the p38 MAP kinase inhibitor may inhibit the release of IP 10 from endothelial cells, preferably in a dose-dependent manner.
Type:
Grant
Filed:
June 26, 2017
Date of Patent:
May 24, 2022
Assignee:
Orph Pharma IP Company Limited
Inventors:
Paul Andrew Whittaker, Neil Edward Torbett